Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -301.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $2M | $11M | $13M | $7M | — | — | — |
| Enterprise Value | $-1524989 | $-3258084 | $11M | $12M | $-3963597 | — | — | — |
| P/E Ratio → | -0.10 | — | — | — | — | — | — | — |
| P/S Ratio | 0.61 | 0.33 | 1.18 | 5.08 | 1498.73 | — | — | — |
| P/B Ratio | 0.20 | 0.28 | 4.24 | 2.65 | 0.65 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.53 | 1.22 | 4.59 | -825.23 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.2% | 23.2% | 36.1% | 31.3% | 90.3% | — | — | — |
| Operating Margin | -171.6% | -171.6% | -95.6% | -314.9% | -83511.5% | — | — | — |
| Net Profit Margin | -242.0% | -242.0% | -96.6% | -313.5% | -169771.2% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -301.8% | -301.8% | -242.4% | -99.8% | -73.8% | — | — | — |
| ROA | -170.6% | -170.6% | -122.7% | -77.8% | -119.6% | -791.3% | -1807.2% | -502.0% |
| ROIC | -318.0% | -318.0% | -203.2% | -342.3% | — | — | — | — |
| ROCE | -184.5% | -184.5% | -190.8% | -93.7% | -36.3% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.58 | 0.33 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.73 | 0.15 | -0.26 | -1.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -238.27 | -238.27 | -96.63 | -212.23 | -2.22 | -5.31 | -18.01 | -14.38 |
Net cash position: cash ($6M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.60 | 2.60 | 0.87 | 1.77 | 10.50 | 0.11 | 0.01 | 0.13 |
| Quick Ratio | 2.58 | 2.58 | 0.86 | 1.76 | 10.50 | 0.11 | 0.01 | 0.13 |
| Cash Ratio | 2.22 | 2.22 | 0.36 | 1.26 | 10.02 | 0.10 | 0.01 | 0.12 |
| Asset Turnover | — | 0.56 | 1.44 | 0.31 | 0.00 | — | — | — |
| Inventory Turnover | 88.36 | 88.36 | 216.71 | 94.19 | 0.08 | — | 0.78 | — |
| Days Sales Outstanding | — | 32.10 | 44.41 | 117.01 | 797.10 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $404333 | $291600 | $149967 | $90933 | $245933 | $245933 |
Liquidity and commercial adoption
According to recent market data, BIAF trades at a price-to-sales multiple of 0.61, a valuation that appears to reflect significant investor skepticism regarding the company's ability to reverse its recent 34.18% revenue decline and achieve meaningful commercial scale in the competitive lung cancer diagnostics market.
The current P/S multiple suggests that the market is pricing the company as a distressed asset rather than a growth-stage diagnostic provider. Investors should monitor whether this valuation floor holds as the company continues to burn cash without a clear path to positive earnings or revenue growth.
Based on reported financial figures, BIAF's ROIC has remained deeply negative, reaching -137.9% in 2026Q1, which indicates that the capital deployed into the business is currently failing to generate any economic return and is instead being consumed by high operating costs and R&D requirements.
The persistent decay in return on invested capital suggests that the company's current business model is not yet compounding value for shareholders. This trend warrants further investigation into whether the underlying diagnostic technology can ever achieve the margins necessary to justify the capital intensity of its commercial rollout.
As reported in quarterly filings, the company's cash conversion cycle has shown extreme volatility, swinging from -61 days in 2025Q3 to -22 days in 2026Q1, which suggests that BIAF lacks a stable process for managing its receivables and payables in a predictable manner.
The erratic nature of these efficiency metrics implies that the company's cash flow is highly sensitive to the timing of insurance reimbursements and vendor payments. This lack of operational consistency may exacerbate the company's liquidity challenges as it attempts to scale its diagnostic services.
According to the latest balance sheet data, the current ratio has compressed to 1.36 as of 2026Q1, a notable decline from the 3.65 observed in 2025Q3, indicating that the company's ability to cover short-term obligations is becoming increasingly constrained by its ongoing cash burn.
The rapid deterioration of the current ratio suggests that the company may soon face a liquidity crunch if it cannot secure additional funding or significantly improve its cash collection cycle. Investors should monitor the company's cash runway closely, as the current trajectory appears unsustainable without external capital support.
As indicated by the company's financial profile, the price-to-sales ratio is frequently misapplied to BIAF, as it obscures the underlying lack of gross margin profitability and the high cash burn associated with the company's current diagnostic service model.
Relying on P/S multiples for a pre-profit diagnostic company can be misleading because it ignores the high variable costs and reimbursement risks that prevent revenue from translating into cash flow. Analysts should instead focus on the 'Cash Burn Rate' and 'Reimbursement Capture Rate' to better assess the company's true viability.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIAF stock.
bioAffinity Technologies, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
bioAffinity Technologies, Inc.'s return on equity (ROE) is -301.8%. The historical average is -179.5%.
Based on historical data, bioAffinity Technologies, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
bioAffinity Technologies, Inc. has 23.2% gross margin and -171.6% operating margin.